Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 4/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ATR | Q13535 | 6/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | PDE9A | O76083 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30860948 | 0.85 | CYP4F2 (0.44) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL27228058 | 0.85 | CYP4F2 (0.44) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL24495524 | 0.85 | LMNA (0.45) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL29686827 | 0.85 | LMNA (0.45) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL30840292 | 0.84 | CYP4F2 (0.43) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL15266698 | 0.84 | CYP4F2 (0.43) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL31093707 | 0.82 | CYP4F2 (0.42) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL31093706 | 0.82 | CYP4F2 (0.42) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL31093704 | 0.82 | CYP4F2 (0.42) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL31178788 | 0.82 | CYP4F2 (0.44) | CYP4F2CYP4A11ALDH1A1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078122-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260062412-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2026-03-05 | — | — | US | disclosed |
| EP-4673436-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2026-01-07 | — | — | EP | disclosed |
| EP-4647424-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-11-12 | — | — | EP | disclosed |
| WO-2025136346-A1 | INDAZOLE CONTAINING COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025111513-A1 | COMPOUNDS USEFUL IN THE MODULATION OF KLHDC1 AND KLHDC2 ACTIVITY | NURIX THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| WO-2024179948-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-09-06 | — | — | WO | disclosed |
| WO-2024181437-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | 中外製薬株式会社 | 2024-09-06 | — | — | WO | disclosed |
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024073073-A2 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024006776-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND MEDICAL USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| EP-3560926-B1 | 6-AMINO-7,9-DIHYDRO-8H-PURIN-8-ONE COMPOUNDS AS BRK INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2022-02-23 | — | — | EP | disclosed |
| US-11052091-B2 | BRK inhibitory compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-07-06 | — | — | US | disclosed |
| US-11052091-B2 | BRK inhibitory compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-07-06 | — | — | US | disclosed |
| EP-3560926-A1 | Brk INHIBITORY COMPOUND | Ono Pharmaceutical Co., Ltd. (JP) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018117177-A1 | Brk INHIBITOR COMPOUND | 小野薬品工業株式会社 | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078122-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | PKN3, PKMYT1, IP6K3 | CYP4F2 2371/4885CYP4A11 1913/4885ALDH1A1 3032/4885 |
| US-11052091-B2 | BRK inhibitory compound | BRI3BP, BRSK2, SBK3 | CYP4F2 1514/4885CYP4A11 750/4885ALDH1A1 3137/4885 |
| US-20260062412-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | MYT1, NTMT1, MYL6 | CYP4F2 2104/4885CYP4A11 1959/4885ALDH1A1 2880/4885 |
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | LRRK2, MAP3K20, MAP3K5 | CYP4F2 4767/4885CYP4A11 4739/4885ALDH1A1 4623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.